-- 週三上午晚些時候，歐洲股市在美國交易，美國存託憑證（ADR）走高，標普歐洲精選ADR指數上漲1.98%，至1843.18點。 歐洲大陸方面，領漲的股票包括住宿預訂公司trivago (TRVG)和荷蘭國際集團(ING)，分別上漲14%和5%。緊隨其後的是生物製藥公司Cellectis (CLLS)和桑坦德銀行(SAN)，分別上漲4.8%和4.2%。 歐洲大陸方面，領跌的股票包括網路廣告公司Criteo (CRTO)和石油煉製公司Equinor (EQNR)，分別下跌18%和8.4%。緊隨其後的是半導體公司Sequans Communications (SQNS)和石油天然氣公司Eni (E)，分別下跌5.8%和4.5%。 英國股市漲幅居前的股票包括生技製藥公司Akari Therapeutics (AKTX)和保險公司Prudential (PUK)，分別上漲9.4%和6.2%。緊隨其後的是礦業公司必和必拓集團(BHP Group)和巴克萊銀行(BCS)，分別上漲5.3%和5.2%。 英國和愛爾蘭股市跌幅居前的股票包括生技製藥公司Mereo BioPharma Group (MREO)和NuCana (NCNA)，分別下跌5.1%和4%。其次是石油和天然氣公司BP (BP)和殼牌(SHEL)，分別下跌3.7%和2.7%。
Related Articles
Australia
Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
$APTV$F
Research
Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
$CRTO
Australia
Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%
$OCUL